Apollo Cancer Centre launches CyberknifeS7 FIM robotic radio surgery system

05th August, 2024

South Asia’s first and most advanced robotic radio surgery system

The CyberKnife S7 FIM System is a non-invasive treatment for cancerous and non-cancerous tumors and other conditions where radiation therapy is indicated. It is used to treat conditions throughout the body including brain, lung, spine, prostate and abdominal cancers, and may be an alternative to surgery for patients who have inoperable or surgically complex tumors. Patients previously treated with radiation, who have metastatic lesions or with recurrent cancers, can also benefit from CyberKnife treatment.

The CyberKnife System is the only radiation delivery system that features a radiation delivery device, called a linear accelerator, directly mounted on a robot to deliver the high-energy X-rays or photons used in radiation therapy. It uses real-time image guidance and a robot to deliver doses from thousands of beam angles, setting a new standard for delivery precision anywhere in the body.

Mr. Dinesh Gundu Rao, State Minister for Health and Family Welfare, Govt. Of Karnataka, said, “It is equally commendable by Apollo Cancer Centers to introduce the CK Academia thereby benefitting a larger ecosystem of cancer warriors. We are indeed proud that both the latest technology and the future practitioners/adopters of this technology, will originate from our state.”

Dr Sridhar PS,  Dr Vinay Ural , Dr Vikram Maiya, radiation oncologists, stated “The CyberKnife S7 FIM System redefines the future of radiation therapy, combining speed, precision and Synchrony AI-driven, real-time target tracking with dynamic delivery to deliver precise hypo fractionated SRS/SBRT treatments for a wider range of indications which include benign brain tumors, brain metastases, select medically refractory functional indications: trigeminal neuralgias, cluster headaches, tremors, lesional epilepsy & select extra cranial inoperable cancers of lung,  pancreas, liver, prostate, recurrent Head and neck cancers and metastatic directed therapy to oligomets.”

 

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer